CS
AIM

Credit Suisse’s AIM ImmunoTech AIM Stock Holding History

Credit Suisse’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$3 – 3987
2022
Q4 		– Hold
0
– – – 3885
2022
Q3 		– Hold
0
– – – 4573
2022
Q2 		– Hold
0
– – – 4633
2020
Q3 		– Sell
-177
Closed -$44K – 4261
2020
Q2 		$44K Buy
+177
New +$43K ﹤0.01% 3879
2013
Q3 		– Hold
0
– -$4K – 4579
2013
Q2 		– Hold
0
– – – 4151

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Credit Suisse's AIM Position: Q1 2023 in Review

Credit Suisse held its AIM ImmunoTech (AIM) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3987.

Credit Suisse first reported a position in AIM in Q2 2020 and has held it in 1 quarter since. The position peaked at $44K in Q2 2020. 31 funds tracked by Wall St. Rank hold AIM as of Q1 2023.

  • Credit Suisse held 0 shares of AIM ImmunoTech worth $0 as of Q1 2023.
  • Credit Suisse left its AIM ImmunoTech share count unchanged in Q1 2023.
  • AIM ImmunoTech made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3987 holding.
  • Credit Suisse first reported a position in AIM ImmunoTech in Q2 2020 and has held it in 1 quarter since.
  • Credit Suisse's AIM ImmunoTech position peaked at $44K in Q2 2020.
  • 31 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.